Zhejiang Dinghui Medical Technology Co., Ltd.

1. Preliminary evaluation of the effect of DH001 in preventing cardiac toxicity in cancer patients after using doxorubicin; 2. Explore the appropriate dosage to provide a basis for the dosage of subsequent confirmatory studies; 3. Evaluate the effect of DH001 on the efficacy of doxorubicin in cancer patients; 4. Evaluate the safety of DH001 in cancer patients treated with doxorubicin.

This trial was divided into 2 studies, and the purpose of each study is as follows: Study 1: Primary purpose: To evaluate the safety and tolerability of DH001 after a single oral administration. Secondary purpose: To evaluate the pharmacokinetic characteristics of DH001 after a single oral administration. Study 2: Primary purpose: To evaluate the safety and tolerability of DH001 after multiple oral administration. Secondary purpose: To evaluate the pharmacokinetic characteristics of DH001 after multiple oral administration.